In-home ‘pop-up’ test centres available for tests to be taken within care homes
Advance Tests, a leader in innovative diagnostics, has announced the opening of a new clinic in London to provide diagnostic blood tests to aid in the diagnosis of Alzheimer’s Disease from December 2nd. Along with this new clinic, Advance Tests is also ready to provide in-house pop-up facilities to visit care homes across the UK and delivery the tests as needed for those in care.
The LucentAD™ Complete test offers care homes and retirement communities an advanced, non-invasive blood test to aid in the early detection of Alzheimer’s disease. With groundbreaking accuracy and accessibility, this multi-marker diagnostic tool enables care teams to better understand residents’ cognitive health, facilitating personalized care strategies, including lifestyle adaptations and treatment plans aligned with new therapies approved by the MHRA.
Why LucentAD Complete matters for the Care Sector?
For care homes and retirement communities, early identification of Alzheimer’s-related amyloid pathology can revolutionize care approaches. The LucentAD Complete test delivers:
Immediate Availability: Appointments are now available from December 2nd, years ahead of the NHS trials that are currently underway in the UK. Advance Tests are working with their biotech partner in the US, Lucent Diagnostics, to whom they will be sending samples taken in the UK to be analysed in Lucent’s accredited laboratories. These laboratories are already processing this groundbreaking test for US citizens, all under a regulated framework, having completed clinical trials with results featured in multiple medical journals.
Flexible: Beyond their London clinic, Advance Tests are both looking for permanent clinics across the UK to support demand as well as pop-up sites to ensure that they are bringing this incredible new test to the places where it is needed. They can also organise an in-house pop-up within care facilities for testing their residents.
Non-Invasive Testing: A simple blood test minimizes disruption for residents and avoids the stress of more invasive gold standard diagnostic procedures like lumbar punctures or costly PET scans.
Informed Care Planning: Test results will be provided within 15 days, providing insights that allow caregivers and managers to tailor interventions, including optimized daily activities and diet plans to support brain health.
Dr Simon Worrell and Prof Alan Thornhill at Lucent Laboratories
Multi-Marker Precision: LucentAD Complete combines p-Tau 217 with additional biomarkers (Aβ42/40, GFAP, and NfL), yielding more conclusive results across a broader range of patients compared with single marker tests. This delivers conclusive results that either rules in or rules out the presence of amyloid pathology for 90% of people taking the test. The test meets the Global CEO Initiative on Alzheimer’s Disease’s (CEOi) and the US Alzheimer’s Association (AA) performance standards for plasma-based diagnostic tools.
Access to Advanced Therapies: Ensures residents benefit from the latest MHRA-approved treatments for early-stage Alzheimer’s by aiding in accurate diagnosis that will identify if these new medicines may be appropriate.
Accessible: Priced at £695, the LucentAD Complete test offers a cost-effective alternative to traditional PET scans and lumber punctures which can be significantly more expensive, helping care homes deliver superior care while managing budgets.
A game-changer for care home operations
Care home managers can now equip their staff with critical diagnostic insights, fostering a proactive approach to managing Alzheimer’s. As cognitive symptoms arise, early detection becomes vital to guiding care practices that improve quality of life for residents.
“Our partnership with Quanterix to bring LucentAD Complete to the UK underscores our commitment to making diagnostics accessible to all,” said Dr. Simon Worrell, Founder and Chief Medical Officer of Advance Tests. “This test is a breakthrough tool for care homes and retirement communities, enabling early intervention that can profoundly impact residents’ lives.”
Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research, University of Wolverhampton, commented on the introduction of LucentAD Complete: “Having access to this sophisticated, non-invasive blood test is a game-changer for early Alzheimer’s diagnosis in the UK. By simplifying diagnostics, we’re helping more patients access critical care sooner, especially as new therapies for early-stage Alzheimer’s are becoming available.”
Booking and availability
Testing appointments are available from December 2nd, with bookings now open through www.advancetests.com. Arrangements for in-house pop-up testing centres can be made by calling 0208 149 1290 or completing a Contact Us form on the website.
About Advance Tests: Advance Tests collaborates with leading biotech innovators to deliver advanced diagnostic tools, empowering healthcare providers and the care sector with cutting-edge solutions. Our mission is to remove barriers to early disease detection, supporting improved health outcomes for all.
